GSK 2982772

Drug Profile

GSK 2982772

Alternative Names: GSK2982772

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antipsoriatics
  • Mechanism of Action Receptor-interacting protein serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis; Rheumatoid arthritis; Ulcerative colitis
  • Phase I Autoimmune disorders; Inflammatory bowel diseases

Most Recent Events

  • 11 Oct 2017 Phase-I clinical trials in Autoimmune disorders (In volunteers) in United Kingdom (PO)
  • 01 Oct 2017 GlaxoSmithKline plans a phase I trial for Autoimmune disorders (In volunteers) (NCT03305419)
  • 27 Sep 2017 GlaxoSmithKline initiates enrolment in a phase I trial for Autoimmune disorders in United Kingdom (NCT03266172)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top